A simple dyspnoea scale as part of the assessment to predict outcome across chronic interstitial lung disease

Respirology

Volumn 22, Issue 3, 2017, Pages 501-507

  Khadawardi, Hadeel ^a   Mura, Marco ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

clinical progression; dyspnoea; interstitial lung disease; outcome; pulmonary fibrosis

Indexed keywords

AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FORCED VITAL CAPACITY; HOSPITALIZATION; HUMAN; INTERSTITIAL LUNG DISEASE; LONGITUDINAL STUDY; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH COUNCIL DYSPNEA SCORE; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; RESPIRATORY TRACT DISEASE ASSESSMENT; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SIX MINUTE WALK TEST; SURVIVAL TIME; COMPLICATION; DISEASE EXACERBATION; DYSPNEA; EXERCISE; FIBROSING ALVEOLITIS; MIDDLE AGED; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; VERY ELDERLY; VITAL CAPACITY; WALK TEST;

AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CHRONIC DISEASE; DISEASE PROGRESSION; DYSPNEA; FEMALE; HOSPITALIZATION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG DISEASES, INTERSTITIAL; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PHYSICAL EXERTION; RETROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; VITAL CAPACITY; WALK TEST;

EID: 85001950325     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12945     Document Type: Article

References (31)

1. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, Hirani N, Hubbard R, Lake F, Millar AB et al.; British Thoracic Society Interstitial Lung Disease Guideline Group, British Thoracic Society Standards of Care Committee; Thoracic Society of Australia; New Zealand Thoracic Society; Irish Thoracic Society. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63(Suppl. 5): v1–58.
2. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008; 63: 549–54.
3. Meyer KC. Diagnosis and management of interstitial lung disease. Transl. Respir. Med. 2014; 2: 4.
4. Yorke J, Swigris J, Russell AM, Moosavi SH, Ng Man Kwong G, Longshaw M, Jones PW. Dyspnea-12 is a valid and reliable measure of breathlessness in patients with interstitial lung disease. Chest 2011; 139: 159–64.
5. Holland AE, Dowman LM, Hill CJ. Principles of rehabilitation and reactivation: interstitial lung disease, sarcoidosis and rheumatoid disease with respiratory involvement. Respiration 2015; 89: 89–99.
6. Kozu R, Jenkins S, Senjyu H. Evaluation of activity limitation in patients with idiopathic pulmonary fibrosis grouped according to Medical Research Council dyspnea grade. Arch. Phys. Med. Rehabil. 2014; 95: 950–5.
7. Baddini Martinez JA, Martinez TY, Lovetro Galhardo FP, de Castro Pereira CA. Dyspnea scales as a measure of health-related quality of life in patients with idiopathic pulmonary fibrosis. Med. Sci. Monit. 2002; 8: CR405–10.
8. Murciano D, Pichot MH, Boczkowski J, Sleiman C, Pariente R, Milic-Emili J. Expiratory flow limitation in COPD patients after single lung transplantation. Am. J. Respir. Crit. Care Med. 1997; 155: 1036–41.
9. Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Kato K, Kataoka K, Ogawa T, Watanabe F, Arizono S. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010; 36: 1067–72.
10. Mura M, Porretta MA, Bargagli E, Sergiacomi G, Zompatori M, Sverzellati N, Taglieri A, Mezzasalma F, Rottoli P, Saltini C et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur. Respir. J. 2012; 40: 101–9.
11. Manali ED, Stathopoulos GT, Kollintza A, Kalomenidis I, Milic-Emili J, Sotiropoulou C, Daniil Z, Roussos C, Papiris SA. The Medical Research Council chronic dyspnea score predicts the survival of patients with idiopathic pulmonary fibrosis. Respir. Med. 2008; 102: 586–92.
12. Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, Koth LL, King TE Jr et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest 2014; 145: 723–8.
13. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA et al.; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788–824.
14. Mahler D, Guyatt GH, Jones PW. Clinical measurement of dyspnea. In: Mahler D (ed) Dyspnea. New York, Marcel Dekker, 1998; 149–98.
15. American Thoracic Society standardization of spirometry, 1994 update. Am. J. Respir. Crit. Care Med. 1995; 152: 1107–36.
16. American Thoracic Society statement. Guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 2002; 166: 111–7.
17. Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, Colby TV, du Bois RM, Hansell DM. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am. J. Respir. Crit. Care Med. 2003; 167: 962–9.
18. Martinez TY, Pereira CA, dos Santos ML, Ciconelli RM, Guimarães SM, Martinez JA. Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with idiopathic pulmonary fibrosis. Chest 2000; 117: 1627–32.
19. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dobbels F, Kirk R, Rahmel AO, Stehlik J, Hertz MI. The registry of the international society for heart and lung transplantation: twenty-eighth adult lung and heart-lung transplant report – 2011. J. Heart Lung Transplant. 2011; 30: 1104–22.
20. Holland AE, Fiore JF, Goh N, Symons K, Dowman L, Westall G, Hazard A, Glaspole I. Be honest and help me prepare for the future: what people with interstitial lung disease want from education in pulmonary rehabilitation. Chron. Respir. Dis. 2015; 12: 93–101.
21. Ryerson CJ, Cayou C, Topp F, Hilling L, Camp PG, Wilcox PG, Khalil N, Collard HR, Garvey C. Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: a prospective cohort study. Respir. Med. 2014; 108: 203–10.
22. Ferreira A, Garvey C, Connors GL, Hilling L, Rigler J, Farrell S, Cayou C, Shariat C, Collard HR. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest 2009; 135: 442–7.
23. Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, Landefeld CS, Collard HR. Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest 2011; 139: 609–16.
24. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T. Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157: 785–90.
25. Papiris SA, Daniil ZD, Malagari K, Kapotsis GE, Sotiropoulou C, Milic-Emili J, Roussos C. The Medical Research Council dyspnea scale in the estimation of disease severity in idiopathic pulmonary fibrosis. Respir. Med. 2005; 99: 755–61.
26. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 1005–12.
27. Mura M, Zompatori M, Pacilli AMG, Fasano L, Schiavina M, Fabbri M. The presence of emphysema further impairs physiological function in idiopathic pulmonary fibrosis. Respir. Care 2006; 51: 257–65.
28. Manali ED, Lyberopoulos P, Triantafillidou C, Kolilekas LF, Sotiropoulou C, Milic-Emili J, Roussos C, Papiris SA. MRC chronic Dyspnea Scale: relationships with cardiopulmonary exercise testing and 6-minute walk test in idiopathic pulmonary fibrosis patients: a prospective study. BMC Pulm. Med. 2010; 10: 32.
29. Nakayama M, Bando M, Araki K, Sekine T, Kurosaki F, Sawata T, Nakazawa S, Mato N, Yamasawa H, Sugiyama Y. Physical activity in patients with idiopathic pulmonary fibrosis. Respirology 2015; 20: 640–6.
30. King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L et al.; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2083–92.
31. Guillen-Del Castillo A, Pilar Simeón-Aznar C, Fonollosa-Pla V, Alonso-Vila S, Reverte-Vinaixa MM, Muñoz X, Pallisa E, Selva-O'allaghan A, Fernández-Codina A, Vilardell-Tarrés M. Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM/Scl antibody. Semin. Arthritis Rheum. 2014; 44: 331–7.